Relative to increasing access to epinephrine
House Bill 5443 would allow certain “authorized entities” — such as restaurants, recreation camps, youth sports leagues, amusement parks, colleges, universities, and sports arenas — to acquire and keep epinephrine autoinjectors for emergency use. The bill defines an authorized entity broadly as any organization where allergens capable of causing anaphylaxis may be present. It sets out a framework for obtaining the devices from a department-approved wholesaler, requiring departmental approval and proof that an employee or agent has completed an approved anaphylaxis training program before the entity may maintain and use the autoinjectors.
The bill also authorizes trained employees or agents to administer epinephrine on-site to any person they reasonably believe is experiencing anaphylaxis, even if that person does not have a prescription or prior allergy diagnosis. It requires the devices to be stored in an accessible location, designates trained personnel to oversee storage and maintenance, and directs the Department of Public Health to issue guidance or regulations to implement the law. In addition, the bill provides liability protection for authorized entities and trained staff for actions taken under the section, except in cases of gross negligence or willful or wanton misconduct, and requires incident reporting to the department with annual public summary reporting.
The bill’s impact on state law is to create a new statutory pathway in Chapter 111 for non-medical entities to stock and use epinephrine autoinjectors in emergencies, expanding access beyond individual prescriptions and healthcare settings. It also adds a reporting and oversight structure for the Department of Public Health, which would approve training, oversee compliance, and publish annual aggregate reports. The measure would affect businesses, schools and colleges, camps, sports venues, and other public-facing organizations that may choose to participate.
The general sentiment reflected in the bill’s referral and committee recommendation is favorable, as the House Ways and Means Committee recommended that the underlying bill “ought to pass” with a substitute amendment. No recorded floor votes or committee transcript debate were provided, so there is no evidence of formal opposition in the available materials. The bill appears to be framed as a public health and emergency preparedness measure aimed at reducing the risk of fatal delays in treating anaphylaxis.
The main points of contention likely concern implementation and liability: who qualifies as an authorized entity, what training standards will be required, how quickly staff can respond in emergencies, and whether the liability shield is appropriately balanced. Another possible issue is the administrative burden on entities that choose to stock epinephrine, including reporting requirements, storage obligations, and compliance with department regulations.
The bill would amend Chapter 111 of the General Laws by adding a new section authorizing designated entities to acquire, store, and use epinephrine autoinjectors under specified conditions. It creates a new legal framework for training, storage, administration, reporting, and departmental oversight, and it grants limited immunity from civil liability for actions taken in compliance with the section, except for gross negligence or willful or wanton misconduct. The measure would directly affect restaurants, camps, youth sports leagues, amusement parks, colleges, universities, sports arenas, and similar organizations where allergens may be present, while giving the Department of Public Health authority to approve wholesalers, training, and implementing regulations.
The available legislative context suggests a positive and noncontroversial posture toward the bill. The House Ways and Means Committee recommended passage with an amendment, and there are no recorded votes or transcript excerpts showing opposition. The bill’s purpose is presented as a public health access measure intended to improve emergency response to anaphylaxis, which generally aligns with supportive sentiment.
No specific objections are documented in the provided materials, but the likely areas of debate are the scope of entities covered, the training and approval requirements, the reporting obligations, and the extent of liability protection. Stakeholders that might scrutinize the bill include affected businesses and institutions concerned about compliance costs and legal exposure, as well as public health advocates who may focus on ensuring that training and storage standards are strong enough to make the program effective.